MCID: END086
MIFTS: 50

End Stage Renal Disease

Categories: Nephrological diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for End Stage Renal Disease

MalaCards integrated aliases for End Stage Renal Disease:

Name: End Stage Renal Disease 11 14 75
Chronic Kidney Disease Stage 5 71
End-Stage Kidney Disease 11
End Stage Renal Failure 11
Kidney Failure, Chronic 71

Classifications:



External Ids:

Disease Ontology 11 DOID:783
ICD9CM 34 585.6
UMLS 71 C0022661 C2316810

Summaries for End Stage Renal Disease

Disease Ontology: 11 A chronic kidney disease is characterized by non-functioning kidneys, as the final stage in chronic kidney disease.

MalaCards based summary: End Stage Renal Disease, also known as chronic kidney disease stage 5, is related to chronic kidney disease and microvascular complications of diabetes 5, and has symptoms including cloudy (hemodialysis) (peritoneal) dialysis effluent An important gene associated with End Stage Renal Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are ACE Inhibitor Pathway, Pharmacodynamics and Primary focal segmental glomerulosclerosis (FSGS). The drugs Digoxin and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone marrow and bone, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for End Stage Renal Disease

Diseases related to End Stage Renal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1470)
# Related Disease Score Top Affiliating Genes
1 chronic kidney disease 32.9 THBD RNLS PON1 MYH9 INVS EPO
2 microvascular complications of diabetes 5 32.8 VEGFA SOD2 PON1 ACE
3 focal segmental glomerulosclerosis 5 32.7 CD2AP APOL1 ACTN4
4 autosomal recessive alport syndrome 32.7 MYH9 CD2AP ACTN4 ACE
5 alport syndrome 32.6 MYH9 CFH CD2AP APOL1 ACTN4 ACE
6 focal segmental glomerulosclerosis 2 32.6 CD2AP ACTN4
7 type 1 diabetes mellitus 32.5 VEGFA PVT1 PON1 ACE
8 focal segmental glomerulosclerosis 6 32.4 CD2AP ACTN4
9 nephronophthisis 7 32.4 NEK8 INVS
10 infantile nephronophthisis 32.4 NEK8 INVS
11 nephronophthisis 16 32.4 NEK8 INVS
12 uremia 32.3 PON1 EPO ACE
13 nephronophthisis 9 32.2 NEK8 INVS
14 glomerulonephritis 32.2 MYH9 IL1RN CFH APOL1 ACTN4 ACE
15 peripheral vascular disease 32.0 VEGFA THBD EPO ACE
16 deficiency anemia 32.0 VEGFA SOD2 PON1 HFE EPO CFH
17 polycystic kidney disease 31.9 VEGFA NEK8 INVS EPO ACE
18 kidney disease 31.9 VEGFA THBD RNLS PON1 NEK8 MYH9
19 autosomal dominant polycystic kidney disease 31.8 NEK8 INVS EPO APOL1 ACE
20 diabetes mellitus 31.7 VEGFA THBD SOD2 PVT1 PON1 IL1RN
21 sleep apnea 31.7 VEGFA EPO ACE
22 iga glomerulonephritis 31.7 CFH CD2AP ACE
23 focal segmental glomerulosclerosis 31.7 PON1 MYH9 CD2AP APOL1 ACTN4 ACE
24 type 2 diabetes mellitus 31.6 VEGFA THBD SOD2 PVT1 PON1 IL1RN
25 neuropathy 31.6 VEGFA SOD2 EPO ACE
26 cystic kidney disease 31.6 NEK8 INVS EPO ACE
27 pulmonary edema 31.6 IL1RN EPO ACE
28 interstitial nephritis 31.6 INVS APOL1 ACE
29 acute myocardial infarction 31.5 VEGFA THBD PON1 HFE ACE
30 nephrotic syndrome 31.5 VEGFA PON1 MYH9 EPO CD2AP APOL1
31 stroke, ischemic 31.5 VEGFA THBD SOD2 PON1 ACE
32 pre-eclampsia 31.4 VEGFA THBD PON1 BDKRB2 ACE
33 hypertension, essential 31.4 VEGFA THBD SOD2 RNLS PON1 MYH9
34 lipoprotein quantitative trait locus 31.4 VEGFA THBD PON1 IL1RN ACE
35 ischemia 31.3 VEGFA SOD2 PON1 IL1RN EPO ACE
36 renal artery disease 31.3 EPO APOL1 ACE
37 blood platelet disease 31.3 VEGFA THBD MYH9 EPO CFH
38 chronic pyelonephritis 31.3 EPO ACE
39 heart disease 31.3 VEGFA THBD SOD2 PON1 IL1RN HFE
40 eclampsia 31.2 VEGFA THBD ACE
41 antiphospholipid syndrome 31.2 THBD PON1 CFH
42 myocardial infarction 31.2 VEGFA THBD SOD2 PON1 IL1RN HFE
43 membranoproliferative glomerulonephritis 31.1 THBD CFH APOL1 ACE
44 lipoid nephrosis 31.1 CD2AP APOL1 ACTN4
45 thrombocytopenia 31.1 VEGFA THBD MYH9 IL1RN EPO CFH
46 hypertensive encephalopathy 31.1 VEGFA EPO ACE
47 angioedema 31.1 BDKRB2 BDKRB1 ACE
48 hypertensive retinopathy 31.0 VEGFA CFH ACE
49 lung disease 31.0 VEGFA SOD2 IL1RN ACE
50 kidney papillary necrosis 31.0 APOL1 ACE

Graphical network of the top 20 diseases related to End Stage Renal Disease:



Diseases related to End Stage Renal Disease

Symptoms & Phenotypes for End Stage Renal Disease

UMLS symptoms related to End Stage Renal Disease:


cloudy (hemodialysis) (peritoneal) dialysis effluent

MGI Mouse Phenotypes related to End Stage Renal Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 ACE ACTN4 BDKRB1 BDKRB2 CD2AP CFH
2 cardiovascular system MP:0005385 10.19 ACE ACTN4 APOL1 BDKRB1 BDKRB2 CD2AP
3 renal/urinary system MP:0005367 10.17 ACE ACTN4 BDKRB2 CD2AP CFH INVS
4 cellular MP:0005384 10.1 ACE ACTN4 BDKRB2 EPO HFE IL1RN
5 immune system MP:0005387 10.03 ACE ACTN4 BDKRB1 BDKRB2 CD2AP CFH
6 liver/biliary system MP:0005370 10.01 ACE ACTN4 EPO HFE INVS SOD2
7 hematopoietic system MP:0005397 9.86 ACE ACTN4 BDKRB1 BDKRB2 CD2AP CFH
8 mortality/aging MP:0010768 9.47 ACE ACTN4 BDKRB2 CD2AP CFH EPO

Drugs & Therapeutics for End Stage Renal Disease

Drugs for End Stage Renal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 554)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Digoxin Approved Phase 4 20830-75-5 3062 2724385 30322
2
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
3
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
4
Candesartan cilexetil Approved Phase 4 145040-37-5
5
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
6
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
7
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
8
Capsaicin Approved Phase 4 404-86-4 1548943
9
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
10
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
11
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
12
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
13
Nadroparin Approved, Investigational Phase 4
14
Lactitol Approved, Investigational Phase 4 585-86-4 157355
15
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
16
Rivaroxaban Approved Phase 4 366789-02-8 9875401
17
Allopurinol Approved Phase 4 315-30-0 2094 135401907
18
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2
19
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
20
Amlodipine Approved Phase 4 88150-42-9 2162
21
Bisoprolol Approved Phase 4 66722-44-9 2405
22
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
23
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4
24
Ribavirin Approved Phase 4 36791-04-5 37542
25
Alemtuzumab Approved, Investigational Phase 4 216503-57-0
26
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
27
Iron Approved Phase 4 7439-89-6 29936
28
Taurolidine Approved, Investigational Phase 4 19388-87-5
29
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
30
Argatroban Approved, Investigational Phase 4 74863-84-6 152951 92722
31
Colchicine Approved Phase 4 64-86-8 2833 6167
32
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
33
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
34
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
35
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
36
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
37
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
38
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
39
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
40
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
41
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
42
Basiliximab Approved, Investigational Phase 4 179045-86-4
43
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
44
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
45
Remifentanil Approved Phase 4 132875-61-7 60815
46
Desflurane Approved Phase 4 57041-67-5 42113
47
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
48
Reviparin Approved, Investigational Phase 4 9041-08-1
49
Eplerenone Approved Phase 4 107724-20-9 443872
50
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290

Interventional clinical trials:

(show top 50) (show all 1848)
# Name Status NCT ID Phase Drugs
1 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
2 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
3 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
4 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
5 A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery Unknown status NCT02447796 Phase 4 Propofol;Dexmedetomidine
6 Hypervolemia and Treatment Guided by Bioimpedance in End Stage Renal Disease Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4
7 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
8 Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients Unknown status NCT00532597 Phase 4
9 The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
10 The Association Between Body Composition and Biomarkers in Hemodialysis Patients Unknown status NCT01103167 Phase 4
11 Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients Unknown status NCT04054128 Phase 4 Sodium Bicarbonate 7.5% Injection;Heparin Sodium, 1000 Units/mL Injectable Solution 1
12 Efficacy and Safety of Local Application of Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection: A Double-Blind, Stratified Randomized Controlled Trial Unknown status NCT02547103 Phase 4
13 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
14 Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes Unknown status NCT01635387 Phase 4 aliskiren
15 Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Continuous Ambulatory Peritoneal Dialysis Patients: An Open-Label Randomized-Controlled Trial Unknown status NCT03953950 Phase 4 Spironolactone;Losartan
16 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
17 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
18 Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease Unknown status NCT02452437 Phase 4 Oxycodone
19 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
20 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
21 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
22 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
23 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
24 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
25 Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
26 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
27 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
28 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril
29 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
30 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
31 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
32 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
33 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction-a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide
34 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
35 Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure Unknown status NCT03682952 Phase 4 Alprostadil Injection;Beraprost sodium tablets
36 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
37 Low-molecular Heparin Infusion as Anticoagulation for Nocturnal Home Hemodialysis Unknown status NCT02957877 Phase 4 Nadroparin;Unfractionated heparin
38 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
39 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
40 Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study Unknown status NCT01631058 Phase 4 Everolimus
41 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
42 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Unknown status NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
43 the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure Unknown status NCT03427944 Phase 4 Calcium Dobesilate group;Conventional Treatment group
44 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
45 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
46 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4 Allopurinol;Placebo (for allopurinol)
47 Erythropoietins in Management of Anemia of End Stage Renal Disease: A Prospective Study From Qatar. Completed NCT02049346 Phase 4 Epoetin alpha or beta (Epoetin group);Darbepoetin alfa;Methoxy polyethylene glycol-epoetin beta
48 A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00414440 Phase 4 Placebo;Everolimus
49 Streptococcus Pneumoniae Colonization and Immunogenicity of 13-valent Conjugate Pneumococcal Vaccine in Patients 50 Years or Older With End Stage Renal Disease on Dialysis. Completed NCT01974817 Phase 4
50 Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis. Completed NCT04085562 Phase 4 Bisoprolol Fumarate 5-10 mg;Amlodipine 5-10 mg

Search NIH Clinical Center for End Stage Renal Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aluminum carbonate
basic aluminum carbonate gel
Bumetanide
calcium acetate
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Cholecalciferol
Dihydrotachysterol
dihydroxyaluminum sodium carbonate
Ethacrynate Sodium
Ethacrynic Acid
Furosemide
magaldrate
Magnesium Hydroxide
MILK OF MAGNESIA
torsemide

Genetic Tests for End Stage Renal Disease

Anatomical Context for End Stage Renal Disease

Organs/tissues related to End Stage Renal Disease:

MalaCards : Kidney, Bone Marrow, Bone, Endothelial, Colon, Heart, Liver

Publications for End Stage Renal Disease

Articles related to End Stage Renal Disease:

(show top 50) (show all 40985)
# Title Authors PMID Year
1
Establishment of Reference Values for Non-HLA Antibodies in Patients With End-stage Renal Disease. 62
36281519 2023
2
Prognostic Predictors of Mortality in Male Breast Cancer: Outcomes in an Urban Population. 62
36182676 2023
3
Paradigm shift in lifestyle modification for solitary kidney after donor nephrectomy. 62
36444664 2023
4
The role of age on the risk relationship between prediabetes and major morbidities and mortality: Analysis of the Hong Kong diabetes surveillance database of 2 million Chinese adults. 62
36419741 2023
5
Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study. 62
36457651 2023
6
Nicorandil protects podocytes via modulation of antioxidative capacity in acute puromycin aminonucleoside-induced nephrosis in rats. 62
36454699 2022
7
Delayed gastric emptying in nondiabetic patients with end-stage kidney disease. 62
35188060 2022
8
Characteristics and outcomes among pregnant women with end-stage renal disease on hemodialysis. 62
34030571 2022
9
Acute kidney injury in critically ill patients with COVID-19: prevalence, risk factors and mortality in eastern Morocco. 62
36006607 2022
10
An unusual cause of pulmonary infiltrates mimicking pulmonary edema: metastatic calcifications. 62
36204407 2022
11
Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease. 62
36381364 2022
12
Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases. 62
35618410 2022
13
A case series of perioperative anaphylaxis to cefazolin during kidney transplant and review of literature. 62
36126905 2022
14
Evaluation of screening with urine dipsticks and renal ultrasonography for 3-year-olds in Chiba City over 30 years. 62
36056980 2022
15
Abnormal cerebral micro-structures in end-stage renal disease patients related to mild cognitive impairment. 62
36379097 2022
16
Polymorphisms in glucose homeostasis genes are associated with cardiovascular and renal parameters in patients with diabetic nephropathy. 62
36314849 2022
17
Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020. 62
36461735 2022
18
Peritoneal dialysis in the era of COVID-19: experience of a Tunisian center. 62
35913609 2022
19
Addition of glomerular lesion severity improves the value of anemia status for the prediction of renal outcomes in Chinese patients with type 2 diabetes. 62
35188068 2022
20
Utilization of HCV viremic donors in kidney transplantation: a chance or a threat? 62
35260039 2022
21
Fetal therapy of LUTO (lower urinary tract obstruction) - a follow-up observational study. 62
34652254 2022
22
Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis. 62
34969349 2022
23
Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy. 62
35172682 2022
24
Endoscopic sleeve gastroplasty: results from a single surgical bariatric centre. 62
36168089 2022
25
Twelve-Month Outcomes From the Japanese Post-Market Surveillance Study of the Viabahn Endoprosthesis as Treatment for Symptomatic Peripheral Arterial Disease in the Superficial Femoral Arteries. 62
34905961 2022
26
Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease. 62
35373711 2022
27
Safe administration of temozolomide in end-stage renal disease patients. 62
36457294 2022
28
Association between cause of kidney failure and fracture incidence in a national US dialysis population cohort study. 62
36381373 2022
29
[Renal manifestations in connective tissue diseases]. 62
36348023 2022
30
Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis. 62
36475355 2022
31
Clinicopathological characteristics and risk factors in elderly patients with biopsy-proven IgA nephropathy. 62
35766236 2022
32
Plasma porphyrins among end stage renal disease patients and cutaneous symptoms- is there still an association? 62
36281443 2022
33
The problem of pulmonary arterial hypertension in end-stage renal disease: can peritoneal dialysis be the solution. 62
36471276 2022
34
Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). 62
36306678 2022
35
DXA-derived advanced hip analysis and the trabecular bone score in end-stage kidney disease secondary to type 1 diabetes. 62
36315195 2022
36
End-stage renal disease: incidence and prediction by coronary heart disease, and educational level. Follow-up from diagnosis of childhood-onset type 1 diabetes throughout Norway 1973-2017. 62
35398254 2022
37
Anti-glomerular basement membrane disease: Treatment outcome of cyclophosphamide vs. rituximab induction therapy regimen. 62
36282172 2022
38
Impact of the Kidney Transplantation Moratorium in France Because of the COVID-19 Pandemic: A Cohort-based Study. 62
36195001 2022
39
Lentiviral vector mediated gene therapy for type I Dent disease ameliorates Dent disease-like phenotypes for three months in ClC-5 null mice. 62
36284768 2022
40
Caring for parents with end-stage renal disease: What do adult children face and how do they cope? 62
34897863 2022
41
Patients with sickle cell disease who develop end-stage kidney disease continue to experience poor survival - A 19-year United States Renal Data System study. 62
36191963 2022
42
Sickle Cell Disease and the Kidney: Filters Gone Awry. 62
36400541 2022
43
Cardiovascular outcomes of transradial versus transfemoral percutaneous coronary intervention in End-Stage renal Disease: A Regression-Based comparison. 62
36051245 2022
44
Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model. 62
36474238 2022
45
Changes in serum pigment epithelium-derived factor levels after kidney transplantation in patients with end-stage renal disease. 62
36217673 2022
46
End-stage renal disease incidence in a cohort of US firefighters from San Francisco, Chicago, and Philadelphia. 62
36268894 2022
47
The prognostic value of speckle tracking echocardiography in patients with end stage renal disease on dialysis. 62
36445672 2022
48
Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned. 62
36469596 2022
49
Delivery of Radioiodine Ablation in a Patient with End-Stage Renal Disease. 62
36398301 2022
50
Feasibility of a break-in period of less than 24 hours for urgent start peritoneal dialysis: a multicenter study. 62
35272577 2022

Variations for End Stage Renal Disease

Expression for End Stage Renal Disease

Search GEO for disease gene expression data for End Stage Renal Disease.

Pathways for End Stage Renal Disease

GO Terms for End Stage Renal Disease

Cellular components related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.66 VEGFA THBD RNLS PON1 IL1RN HFE
2 ciliary inversin compartment GO:0097543 9.13 NEK8 INVS

Biological processes related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to nutrient levels GO:0031667 9.72 SOD2 PON1 ACE
2 response to salt stress GO:0009651 9.67 EPO BDKRB2
3 response to hypoxia GO:0001666 9.65 VEGFA SOD2 EPO ACTN4 ACE
4 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.46 VEGFA ACE
5 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.43 EPO BDKRB2
6 response to lipopolysaccharide GO:0032496 9.32 THBD SOD2 EPO BDKRB1 ACE

Molecular functions related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor receptor binding GO:0005172 9.26 VEGFA CD2AP
2 bradykinin receptor activity GO:0004947 8.92 BDKRB2 BDKRB1

Sources for End Stage Renal Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....